Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MMP-2, MMP-9 and NGAL as Biomarkers for Glioblastoma (GBM) Biomarkers for the Prognosis of Glioblastoma

NCT01493219 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT01493219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01493219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MMP-2, MMP-9 and NGAL as Biomarkers for Glioblastoma (GBM) Biomarkers for the Prognosis of Glioblastoma
Lead sponsor
University of Nebraska
Phase
Observational
Overall status
Completed
Start date
September 20, 2011
Completion date
September 1, 2017
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma